Rain Therapeutics Inc., (“Rain”), a late-stage company developing precision oncology therapeutics, today announced a clinical supply agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the supply of the anti-Programmed Death Ligand-1 (PD-L1) monoclonal antibody, atezolizumab.

Rain Therapeutics Inc., (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will provide a corporate overview at the JP Morgan Chase 40th Annual Healthcare Conference and at the H.C. Wainwright Bioconnect Conference, both conferences being held virtually January 10-13, 2022.

(GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a late-stage company developing precision oncology therapeutics, today announced it will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective as of market open on Monday, December 20, 2021.